PamGene X AACR 2025 Scientific Posters 

These 6 presentations highlight the crucial role of kinase profiling in drug discovery and cancer therapy, demonstrating how PamGene’s technology provides deep insights into kinase activity, helping to uncover therapeutic targets and guide personalized treatments in oncology. Visit us at booth #3355

1. Presentation: OMX-0407 – A spectrum-selective kinase inhibitor shows preclinical efficacy in RCC as well as sarcomas

Session PO.ET05.01 – Cell Cycle Effects of Anticancer Drugs 👉 Access online abstract

Presenter: Ilona Petra Maser, Carolin Strobl, Bettina Bauer, Andreas Schirmer, Moritz Zulley, Carmen Amerhauser, Marisa Stebegg-Wagner, Tiantom Jarutat, Hannes Loferer, Stefan Bissinger

Date: April 27, 2025, 2:00 PM – 5:00 PM

Key Findings:

  • OMX-0407 demonstrated anti-tumor efficacy in RCC and sarcomas, inducing G1 cell cycle arrest and modulating key kinase pathways.
  • PamGene’s Kinase Profiling confirmed the dose-dependent effects in in vitro and in vivo models.
  • OMX-0407 also repolarized the tumor microenvironment, enhancing immune-mediated tumor suppression.

2. Presentation: A novel drug discovery platform identifies epitopes on driver receptors that can be targeted to induce widespread kinase inhibition and cancer cell death

Session PO.ET02.01 – Antibody-Based Cancer Therapeutics 1 👉 Access online abstract

Presenter: Rachel S. Welt, Virginia Raymond, David Kostyal, Sydney Welt

Date: April 28, 2025, 9:00 AM – 12:00 PM

Key Findings:

  • WBMP-4, a monoclonal antibody targeting the IgM subunit of the B-cell receptor (BCR), induces kinase inhibition and apoptosis in B-cell malignancies.
  • PamGene’s Kinase Profiling revealed extensive modulation of kinase activity in lymphoma cells, showing significant changes in over 180 phosphosites.
  • The results support WBMP-4’s potential as a promising tumor-targeted therapy.

3. Presentation: Mapping the hypoxic regulation of IFNγ and TNFα-mediated kinase pathways in melanoma

Session PO.MCB03.01 – Kinases/Phosphatases, Ubiquitin, and Ubiquitin-like Proteins 👉 [Download Poster PDF]

Presenter: Simar Pal Singh, Alex Miranda Rodriguez, Russell W. Jenkins

Date: April 29, 2025, 9:00 AM – 12:00 PM

Key Findings:

  • These results provide valuable insights into hypoxia-driven immune evasion and the response to cytokines in tumors, suggesting potential therapeutic strategies.
  • PamGene’s Kinase Profiling was used to study the effects of cytokines IFNγ and TNFα on melanoma cells under hypoxic conditions.
  • Hypoxia altered kinase dynamics, notably shifting PI3K/AKT and MAPK signaling pathways.

4. Presentation: Pharmacodynamic biomarker modulation by OMX-0407, a novel, spectrum-selective kinase inhibitor for the treatment of angiosarcoma and renal cell carcinoma

Session PO.ET07.01 – Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics 👉 Access online abstract

Presenter: Marisa Stebegg-Wagner, Ilona Petra Maser, Bettina Bauer, Andreas Schirmer, Moritz Zulley, Carmen Amerhauser, Thorsten Meyer, Tiantom Jarutat, Hannes Loferer, Stefan Bissinger

Date: April 29, 2025, 9:00 AM – 12:00 PM

Key Findings:

  • OMX-0407 targets key tyrosine kinases and the SIK family, showing dose-dependent inhibition of SFK phosphorylation.
  • PamGene’s KinomePro confirmed its pharmacodynamic effects, correlating with anti-tumor activity in solid tumors.
  • OMX-0407 showed a complete response in a patient with angiosarcoma.

 

5. Presentation: Distinct kinase signatures define therapeutically relevant subtypes in colorectal cancer

Session PO.CH02.01 – Proteomic Signatures in Cancer 👉 [Download Poster PDF]

Presenter: Gitanjali Dharmadhikari, Simar Pal Singh, Monique Mommersteeg, Liesbeth Houkes, Martijn Dankers

Date: April 28, 2025, 9:00 AM – 12:00 PM

Key Findings:

  • PamGene’s KinomePro identified two distinct molecular subtypes of colorectal cancer based on EPH and SRC kinase activity.
  • Kinase activity correlated with inhibitor sensitivity, supporting the potential of these biomarkers for personalized therapy.
  • Integrating transcriptomics and kinase profiling provided a deeper understanding of CRC molecular heterogeneity.

 

 

6. Presentation: Targeting NRF2-responsive kinases for the treatment of esophageal squamous cell carcinoma

Session PO.ET09.01 – Kinase and Phosphatase Inhibitors 1 👉 Access online abstract

Presenter: Boopathi Subramaniyan, Zhaohui Xiong, Yahui Li, Chorlada Paiboonrungruang, Francis Spitz, M. Ben Major, Xiaoxin Chen

Date: April 28, 2025, 9:00 AM – 12:00 PM

Key Findings:

  • NRF2 has been identified as a key driver in esophageal squamous cell carcinoma (ESCC), with mutation rates of 10%-22%.

  • PamGene’s Kinase Profiling revealed several NRF2-responsive kinases, including PI3K and Akt, in ESCC cells.

  • The combination of NRF2 and PI3K inhibitors showed synergistic effects, highlighting a promising therapeutic strategy for ESCC.